Close Menu

FDA

Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.

Created by BloodPAC members, the resource may serve as a set of generic analytical protocols to help define industry standards for developing liquid biopsy tests.

The tests are designed to detect antibodies against SARS-CoV-2 in order to help identify individuals with an adaptive immune response to the virus.

The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.

 

The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, enabling appropriate treatment options.

The two tests, both of which use RT-PCR technology to detect multiple viral targets, may be performed only by their respective developers.

T2 Bio's T2SARS-CoV-2 Panel detects SARS-CoV-2 within two hours using a nasopharyngeal swab sample and runs on the firm's T2Dx instrument.

Some lab experts say that Abbott's test is open to multiple variables, which could lead to improper use and incorrect test results.

Pages